Abstract
Introduction Investigating acute multifactorial undifferentiated breathlessness and understanding the driving inflammatory processes can be technically challenging in both adults and children. Being able to validate noninvasive methods such as breath analysis would be a huge clinical advance. The ReCIVA® device allows breath samples to be collected directly onto sorbent tubes at the bedside for analysis of exhaled volatile organic compounds (eVOCs). We aimed to assess the feasibility of using this device in acutely breathless patients.
Methods Adults hospitalised with acute breathlessness and children aged 5–16 years with acute asthma or chronic stable asthma, as well as healthy adult and child volunteers, were recruited. Breath samples were collected onto sorbent tubes using the ReCIVA® device and sent for analysis by means of two-dimensional gas chromatography-mass spectrometry (GCxGC-MS). The NASA Task Load Index (NASA-TLX) was used to assess the perceived task workload of undertaking sampling from the patient's perspective.
Results Data were available for 65 adults and 61 children recruited. In total, 98.4% of adults and 75.4% of children were able to provide the full target breath sample using the ReCIVA® device. NASA-TLX measurements were available in the adult population with mean values of 3.37 for effort, 2.34 for frustration, 3.8 for mental demand, 2.8 for performance, 3.9 for physical demand and 2.8 for temporal demand.
Discussion This feasibility study demonstrates it is possible and acceptable to collect breath samples from both adults and children at the bedside for breathomics analysis using the ReCIVA® device.
Abstract
It is feasible to collect breath samples for breath analysis at the bedside using the ReCIVA device in acutely breathless adults and children https://bit.ly/2ZTonWo
Footnotes
Support statement: Research funding was provided by the MRC and EPSRC Stratified Medicine Grant for Molecular Pathology Nodes (grant number MR/N005880/1). The research was supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre – Respiratory and Cardiovascular Themes, NIHR, Leicester Clinical Research Facility, the British Lung Foundation and the Midlands Asthma and Allergy Research Association, to whom we are extremely grateful. The views expressed are those of the author(s) and not necessarily those of the National Health Service and NIHR or the Department of Health. Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: K.A. Holden reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: W. Ibrahim reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: D. Salman reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: R. Cordell reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: T. McNally reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: B. Patel reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: R. Phillips reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: C. Beardsmore reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: M. Wilde reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: L. Bryant reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: A. Singapuri reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: P. Monks reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study.
Conflict of interest: C. Brightling reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study; grants and personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Merck, Gossamer, 4DPharma, Boehringer Ingelheim and Mologic, personal fees from TEVA, grants from Genentech/Roche, and personal fees from Sanofi, outside the submitted work.
Conflict of interest: N. Greening reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study; research funding and lecture honoraria from GSK, and lecture honoraria and conference travel from AstraZeneca, Boehringer Ingelheim and Chiesi, outside the submitted work.
Conflict of interest: P. Thomas reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study; and grants from TOXI-triage (this project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 653409), outside the submitted work.
Conflict of interest: S. Siddiqui reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study; grants from TOXI-triage (this project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 653409), personal fees from Owlstone Medical Ltd and Mundipharma, and advisory board fees from GlaxoSmithKline, AstraZeneca, Novartis, Chiesi and Roche, outside the submitted work.
Conflict of interest: E.A. Gaillard reports grants from the Medical Research Council and the Engineering and Physical Sciences Research Council EMBER Node Consortium, the British Lung Foundation, and the Midlands Asthma and Allergy Research Association, during the conduct of the study; consultancy fees paid to the University of Leicester from Boehringer Ingelheim and Anaxsys, investigator-led research grants from Circassia, Gilead and Chiesi Ltd, and a research collaboration grant from Medimmune, outside the submitted work.
- Received March 6, 2020.
- Accepted July 17, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
